Fig. 6
From: Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer
Correlation between the signature and tumor dryness, genomic instability and drug sensitivity. (A) The signature is nor correlated with the DNAss of COAD patients. (B) The risk score of the signature is negatively correlated with the RNAss of COAD patients, ***P < 0.001. (C) The risk score of the signature is not correlated with the MSI of COAD patients. (D-I) Patients with low risk are more sensitive to Alpelisib, AZ960, BMS-754,807, Doramapimod, JAK_8517 and Taselisib, ***P < 0.001